Positive News SentimentPositive NewsNASDAQ:FHTX Foghorn Therapeutics (FHTX) Stock Price, News & Analysis $4.88 +0.03 (+0.51%) Closing price 03:59 PM EasternExtended Trading$4.88 -0.01 (-0.20%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Foghorn Therapeutics Stock (NASDAQ:FHTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Foghorn Therapeutics alerts:Sign Up Key Stats Today's Range$4.76▼$4.9550-Day Range$3.60▼$5.5152-Week Range$3.27▼$6.95Volume260,547 shsAverage Volume213,784 shsMarket Capitalization$286.80 millionP/E RatioN/ADividend YieldN/APrice Target$11.43Consensus RatingModerate Buy Company Overview Foghorn Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of novel epigenetic therapies for cancer. The company leverages its proprietary Targeted Protein Discovery Platform to identify and design small-molecule inhibitors that modulate chromatin regulatory proteins involved in tumor growth and survival. By targeting the mechanisms that control gene expression, Foghorn seeks to address unmet needs in oncology through precision medicine. The company’s lead candidate, FHD-286, is a selective inhibitor of variant SWI/SNF chromatin remodeling complexes and is currently being evaluated in Phase 1 clinical trials for patients with solid tumors harboring specific SMARCA2 and SMARCA4 alterations. In addition to FHD-286, Foghorn maintains a pipeline of preclinical programs aimed at other chromatin targets, with the goal of advancing multiple development candidates into the clinic over the coming years. Founded in 2015 and headquartered in Cambridge, Massachusetts, Foghorn Therapeutics was established with support from leading life-science investors. The company operates research and development activities in the United States and collaborates with academic and industry partners to accelerate the translation of its discoveries into potential therapeutic options for patients worldwide. Under the leadership of President and Chief Executive Officer Robert Mulroy, PhD, Foghorn has built a multidisciplinary team with expertise in epigenetics, medicinal chemistry, structural biology and translational medicine. The company’s strategic vision emphasizes innovation in chromatin biology and a commitment to developing differentiated treatments for oncology.AI Generated. May Contain Errors. Read More Foghorn Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks73rd Percentile Overall ScoreFHTX MarketRank™: Foghorn Therapeutics scored higher than 73% of companies evaluated by MarketBeat, and ranked 206th out of 851 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingModerate Buy Consensus RatingFoghorn Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 1 strong buy rating, 6 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialFoghorn Therapeutics has a consensus price target of $11.43, representing about 134.0% upside from its current price of $4.89.Amount of Analyst CoverageFoghorn Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Foghorn Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Foghorn Therapeutics are expected to grow in the coming year, from ($0.98) to ($0.87) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Foghorn Therapeutics is -4.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Foghorn Therapeutics is -4.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Foghorn Therapeutics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.61% of the float of Foghorn Therapeutics has been sold short.Short Interest Ratio / Days to CoverFoghorn Therapeutics has a short interest ratio ("days to cover") of 8.56.Change versus previous monthShort interest in Foghorn Therapeutics has recently decreased by 5.32%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldFoghorn Therapeutics does not currently pay a dividend.Dividend GrowthFoghorn Therapeutics does not have a long track record of dividend growth. News and Social Media3.7 / 5News SentimentN/A News SentimentFoghorn Therapeutics has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.86 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Foghorn Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for FHTX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added Foghorn Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Foghorn Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders9.02% of the stock of Foghorn Therapeutics is held by insiders.Percentage Held by Institutions61.55% of the stock of Foghorn Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Foghorn Therapeutics' insider trading history. Receive FHTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Foghorn Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. FHTX Stock News HeadlinesFoghorn Therapeutics (NASDAQ:FHTX) Cut to Sell at Wall Street ZenJune 22, 2026 | americanbankingnews.comFoghorn Therapeutics Inc. (NASDAQ:FHTX) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJune 19, 2026 | americanbankingnews.comThe startup growing 23 times faster than NvidiaAn official SEC document contains a name Elon Musk revealed on page 146 - a startup that one analyst believes could be the next monster IPO on Wall Street. This company is growing 23 times faster than Nvidia. The Atlantic called it 'the fastest-growing business in the history of capitalism.' It has nothing to do with robots, self-driving cars, or rockets.June 30 at 1:00 AM | Brownstone Research (Ad)Foghorn Therapeutics Inc. (FHTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 9, 2026 | seekingalpha.comFoghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026June 5, 2026 | globenewswire.comFoghorn Therapeutics Highlights Q1 Progress in Oncology PipelineMay 22, 2026 | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Foghorn Therapeutics (FHTX) and Monte Rosa Therapeutics (GLUE)May 18, 2026 | theglobeandmail.comFoghorn Therapeutics to Participate in Three Upcoming Investor Conferences in MayMay 12, 2026 | globenewswire.comSee More Headlines FHTX Stock Analysis - Frequently Asked Questions How have FHTX shares performed this year? Foghorn Therapeutics' stock was trading at $5.40 at the beginning of 2026. Since then, FHTX shares have decreased by 9.5% and is now trading at $4.8850. How were Foghorn Therapeutics' earnings last quarter? Foghorn Therapeutics Inc. (NASDAQ:FHTX) announced its quarterly earnings results on Thursday, May, 7th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.28) by $0.01. The business had revenue of $3.27 million for the quarter, compared to the consensus estimate of $7.94 million. When did Foghorn Therapeutics IPO? Foghorn Therapeutics (FHTX) raised $120 million in an initial public offering (IPO) on Friday, October 23rd 2020. The company issued 7,500,000 shares at $15.00-$17.00 per share. Goldman Sachs, Morgan Stanley and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. How do I buy shares of Foghorn Therapeutics? Shares of FHTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Foghorn Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Foghorn Therapeutics investors own include Tesla (TSLA), JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD), NVIDIA (NVDA), Netflix (NFLX), Meta Platforms (META) and Alphabet (GOOG). Company Calendar Last Earnings5/07/2026Today6/30/2026Next Earnings (Estimated)8/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (5m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 FHTX's financial health is in the Yellow zone, according to TradeSmith. FHTX has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:FHTX CIK1822462 Webfoghorntx.com Phone617-586-3100FaxN/AEmployees120Year Founded2016Price Target and Rating Average Price Target for Foghorn Therapeutics$11.43 High Price Target$13.00 Low Price Target$10.00 Potential Upside/Downside+134.0%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($1.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$74.28 million Net Margins-266.88% Pretax Margin-266.88% Return on EquityN/A Return on Assets-35.38% Debt Debt-to-Equity RatioN/A Current Ratio2.92 Quick Ratio2.92 Sales & Book Value Annual Sales$30.91 million Price / Sales9.28 Cash FlowN/A Price / Cash FlowN/A Book Value($1.92) per share Price / Book-2.54Miscellaneous Outstanding Shares58,710,000Free Float53,418,000Market Cap$286.80 million OptionableOptionable Beta2.89 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:FHTX) was last updated on 6/30/2026 by MarketBeat.com Staff. From Our PartnersPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | Sponsored[Free Report] The 11-Hour Options Guide for Beginners - trade and ticker includedTired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe startup growing 23 times faster than NvidiaAn official SEC document contains a name Elon Musk revealed on page 146 - a startup that one analyst believes ...Brownstone Research | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely, LLC | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredForget the million-dollar nest egg — you only need THIS muchNearly 2 in 3 Americans fear running out of money more than death - and chasing a $1.5 million nest egg isn't ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Foghorn Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Foghorn Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free FHTX Stock Alerts